In many mass tort cases, and particularly in cases involving exposure to a substance with a long latency period, defendants and plaintiffs must rely on documents created decades ago.
If the turbulence of 2018 caused business executives grief, the year ahead is unlikely to provide much relief. Foremost is the United States-Mexico-Canada Agreement (USMCA). If most political pundits are correct, the three governments will likely be able to ratify the USMCA in time to be in full fo
The Department of Health and Human Services (HHS) has issued a proposed rule (PR) which would require any television advertisement for a drug or biological covered by Medicare or Medicaid to include a disclosure of the product’s “current list price” for a “typical” thirty day supply.
On October 11, the United States Patent and Trademark Office published a new final rule altering the claim construction standard applied in inter partes review, post grant review, and covered business method review proceedings.
In a key decision earlier this month with potentially hefty ongoing implications for developers and property owners, the U.S. Court of Appeals for the Third Circuit held a chemical company liable for nearly $1 million in pre-acquisition cleanup costs.
A German court in Stuttgart has ordered Porsche SE to pay its investors for failing to provide timely information about the Volkswagen diesel emissions scandal.
On Friday, October 19, 2018, the Maryland Attorney General (AG) filed a petition for writ of certiorari to the United States Supreme Court (SCOTUS) regarding Maryland’s drug price gouging law (the Law)– the first state law enacted to prohibit alleged drug price gouging by manufacturers.
Long-anticipated changes to California’s Proposition 65 warning requirements took effect on August 30, 2018, through amendments and new rules issued by the California Office of Environmental Health Hazard Assessment.
President Trump is expected to sign into law a bill which will – among other things – expand the scope of the Open Payments reporting requirements mandated by Section 6002 of the Patient Protection and Affordable Care Act (often referred to as the Sunshine Act).
Long-anticipated changes to California’s Proposition 65 warning requirements took effect on August 30, 2018, through amendments and new rules issued by the California Office of Environmental Health Hazard Assessment.
Efforts to update FDA’s personal care products regulations continue as Rep. Jan Schakowsky (D-IL) recently introduced H.R. 6903, the “Safe Cosmetics and Personal Care Products Act of 2018.”
On September 28, 2018, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed an amended complaint to revive its lawsuit seeking to block implementation and enforcement of California’s drug price transparency law.
In the last hour of the last day of last month, with 30 minutes to spare, US Trade Representative Lighthizer met the US self-imposed deadline and formally sent to Congress the agreed-upon text of a US-Mexico-Canada Agreement, or USMCA.
